We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App





AbbVie Announces Collaboration to Develop Monoclonal Antibody Therapy for COVID-19

By HospiMedica International staff writers
Posted on 09 Jun 2020
A new collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19 will focus on advancing a fully human, neutralizing antibody which targets the conserved domain of the spike protein of SARS-CoV-2.

AbbVie (North Chicago, IL, USA), University of Utrecht (Utrecht, the Netherlands), the Erasmus Medical Centre (Rotterdam, the Netherlands), and biotech company Harbor BioMed (Cambridge, MA, USA) have entered into a collaboration under which AbbVie will support UU, EMC and HBM through the preclinical activities, while simultaneously undertaking preparations for later stage preclinical and clinical development work. More...
AbbVie will receive an option to exclusively license the antibody from the three parties for therapeutic clinical development and commercialization worldwide.

The fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM targets a conserved region of the virus' spike protein. In cell culture studies the antibody blocked infection by the SARS-CoV-2 and a second coronavirus SARS-CoV. The antibody is fully human, which is designed to facilitate its development and minimize immune-related side effects.

"Treatment and prevention of COVID-19 remains a critical global need. The antibody discovered by UU, EMC and Harbour BioMed is extremely promising based on the mechanism by which it targets the virus and on its developability as a fully human protein," said Tom Hudson, M.D., Senior Vice President, Research and Development and Chief Scientific Officer, AbbVie. "We look forward to working with this outstanding team to advance this antibody towards clinical trials."

"AbbVie is a global leader in developing innovative antiviral therapies," said Dr. Jingsong Wang, Founder, Chairman & Chief Executive Officer of HBM. "This collaboration will greatly accelerate our efforts to bring this antibody forward into clinical trials as quickly as possible and contribute a solution to this pandemic."

"The SARS-CoV-2 pandemic has highlighted the importance of understanding coronavirus biology," said Berend-Jan Bosch, PhD, Associate Professor, Research leader at UU. "The collaboration with AbbVie provides an excellent opportunity to translate our research into a clinical candidate with great potential for advancing the fight against this disease."

"The collaboration is an endorsement of our approach to fully human antibody discovery and development. Through this collaboration, we are well positioned to move rapidly towards clinical trials," said Frank Grosveld, PhD, Academy Professor of Cell Biology, EMC, Rotterdam and Founding Chief Scientific Officer at Harbour BioMed.

Related Links:
AbbVie
University of Utrecht
Erasmus Medical Centre
Harbor BioMed



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: iStock

Updated Head Injury Guidelines Support Risk-Based CT and Observation Decisions

Head injuries are a common reason for emergency department visits, with most cases classified as mild. However, clinicians must identify patients at risk of intracranial bleeding or other serious injuries... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image Credit: Adobe Stock

Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis

Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.